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Critical limb ischemia (CLI) continues to form a substantial burden on Western healthcare. Many patients still face
amputation as a last treatment option. Autologous bone marrow (BM)-derived cell administration has emerged as a
potential new treatment, but proof for sustainable clinical effects of BM-derived cell therapy in CLI is still lacking. The
JUVENTAS (reJUVenating ENdothelial progenitor cells via Transcutaneous intra-Arterial Supplementation) trial is the
first randomized, placebo-controlled, double-blinded clinical trial on repeated intra-arterial BM mononuclear cell
(MNC) infusion in 110 to 160 CLI patients, designed to provide definite proof for the efficacy of stem cell therapy.
Primary outcome is the incidence of major amputation at 6 months. Inclusion of patients is well underway. If BM-MNC
cells therapy is beneficial, it could become a novel treatment to prevent amputation in patients with CLI. (J Vasc Surg
2010;51:1564-8.)Critical limb ischemia (CLI) imposes a large burden on
Western healthcare, as a considerable number of patients
with CLI (40%) are ineligible for surgical or radiological
revascularization. The prognosis is poor,1 and with the lack
of pharmacological treatments and other effective thera-
pies, amputation is often the only treatment option left.
Consequently, development of new revascularization ther-
apies for CLI is of great importance. Bone marrow (BM)-
derived endothelial progenitor cells (EPC) have been iden-
tified as a potential new therapeutic tool in the treatment of
CLI.
Since the first observation of their presence in periph-
eral blood in the 1990s, increasing evidence indicates that
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1564EPC contribute to postnatal neovascularization by homing
and incorporation into sites of new vessel formation.2,3
Encouraging results of small clinical studies on progenitor
cell-based therapy have been reported in patients with CLI.
Thus far, over 30 clinical studies have reported on the use of
BM or peripheral blood (PB)-derived progenitor cells in
patients with peripheral arterial occlusive disease (PAOD)
or CLI (for an overview of design, patient number, route
of administration, and outcome of these studies, see
Sprengers et al4). Almost all studies reported beneficial
results on clinical parameters. However, most of the studies
have been small and lacked double-blind controls. Large,
randomized, placebo-controlled trials are needed to evalu-
ate the effects of cell-based therapy in CLI.
The JUVENTAS (reJUVenating ENdothelial progen-
itor cells via Transcutaneous intra-Arterial Supplementa-
tion) trial is an investigator-driven trial that examines the
potential clinical effects of repeated intra-arterial infusion of
BM-MNC in CLI patients. In addition, it studies the
functional characteristics of BM-MNC obtained from CLI
patients and will relate BM-MNC dysfunction to clinical
outcome. This translational approach may lead to the iden-
tification of predictive assays or markers for therapeutic
efficacy and may eventually yield strategies to improve
therapeutic efficacy. To our knowledge, this is the first
translational trial of its size that will investigate the clinical
effects of intra-arterial infusion of BM-MNC in patients
with CLI. This clinical update will cover the design of the
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solved issues on cell therapy in CLI patients.
JUVENTAS TRIAL STUDY DESIGN
The JUVENTAS trial has a randomized, double-blind,
placebo-controlled design. A total number of 110 to 160
patients with proven chronic CLI or selected patients with
severely invalidating intermittent claudication (claudicants
on the verge of rest pain), who are not candidates for
surgical or radiological revascularization (as decided by a
multidisciplinary team of vascular surgeons and radiolo-
gists) will be included in the trial. Risk factors for cardio-
vascular disease are treated according to Dutch practice
guidelines. Patients are screened for eligibility according to
the criteria listed in Table. After obtaining written informed
consent, patients are randomized by the Data Safety Mon-
itoring Committee by means of a computerized random-
ization table to either repeated intra-arterial infusion of
BM-MNC or placebo (a flow chart of the study design is
shown in the Fig). The Gene and Cell Therapy Facility of
the University Medical Center Utrecht is informed about
the randomization result after BM aspiration. The steering
committee and clinical staff remain blinded to the treat-
ment allocation.
BM aspirates are obtained in all patients. A total volume
of 100 ml BM is aspirated from the iliac crest under local
anesthetic and conscious sedation according to local rou-
tine. Seven ml of BM aspirate is kept separately for funda-
mental research purposes. The remaining BM aspirate is
used for purification of BM-MNC by density gradient
centrifugation. After washing, theMNC is resuspended in a
physiological salt solution containing 10% human serum
albumin (HSA). For the study group, one-third of the
remaining cells is prepared for direct infusion, while two-
thirds of the cells are cryopreserved using 10% dimethylsulf-
oxide (DMSO) and stored for later infusions. For the
control group, a placebo is prepared using autologous
erythrocytes to match the color of the BM-derived cellular
product in order to guarantee the double blinding proce-
dure at the time of infusion. One-third of the placebo is
prepared for direct infusion, while two-thirds of the pla-
cebo are cryopreserved and stored in the same manner as
performed for the study group. Patients are scheduled for
Table. Inclusion and exclusion criteria of the JUVENTAS
Inclusion criteria
● Age  18 years
● Severe PAOD (Fontaine class IIb, III, and/or IV)
● Invalidating intermittent claudication
● Persistent recurring rest pain requiring analgesia
● Non-healing ulcers present for 4 weeks without evidence o
improvement in response to conventional therapies
● Ankle brachial index  0.6 or unreliable (non-compressible or
in proportion to the Fontaine classification)
● Not eligible for surgical or radiological revascularization
● Written informed consentthree visits at the clinical research unit for intra-arterialinfusion of BM-MNC or placebo. The first infusion is
performed within 4 hours after BM aspiration. The subse-
quent two infusions take place at 3-week intervals. Syringes
without information about the containing product (BM-
MNC or placebo) are provided by the local Gene and Cell
Therapy Facility to the clinical staff at the time of cell or
placebo infusion. An experienced operator will slowly ad-
minister 10 ml of BM-MNC or placebo into the common
femoral artery of the affected leg by hand injection.
Clinical evaluation is performed by the same investiga-
tor at baseline and at 2- and 6-month follow up. The
primary outcome is incidence ofmajor amputation (defined
Fig. Flow chart of the study design of the JUVENTAS Trial.ABI,
Ankle-brachial pressure index; CLI, critical limb ischemia; MRA,
magnetic resonance angiography; QoL, quality of life; TcpO2,
transcutaneous oxygen pressure.
Exclusion criteria
● History of neoplasm or malignancy in the past 10 years
● Serious known concomitant disease with life expectancy of
less than one year
● (Anticipated) inability to obtain 100 ml of bone marrow as-
pirate
● Known infection with human immunodeficiency virus
(HIV), hepatitis B or hepatitis C virus
● Follow-up impossibletrial
f
notas being sited through or above the ankle joint) at 6
JOURNAL OF VASCULAR SURGERY
June 20101566 Sprengers et almonths. Secondary outcomes are the incidence of minor
amputations (sited more distal than the ankle joint),
changes in the number and extent of leg ulcers, resolve-
ment of rest pain or improvement of pain-free walking
distance, improvement of ankle-brachial index and transcu-
taneous oxygen pressure, and changes in quality of life.
Standardized magnetic resonance imaging/angiography
(MRI/MRA) imaging is performed at the time of inclusion
and after 6-month follow up to allow for objectivemeasures
for neovascularization (eg, collateral vessel formation, flow
measurements, perfusion measurements).
ANALYSES
The sample size for the JUVENTAS trial is based on a
6-month risk of major amputation in patients with unre-
constructed chronic critical leg ischemia of 42%5 and an
estimated reduction of the risk of major amputation by
BM-MNC infusion of 50%. Previously, predominantly
Asian studies reported marked beneficial effects of BM-
MNC therapy, claiming prevention of limb amputation in
73% and 91%.6,7 For Western patients, who often have
multiple risk factors, fewer data are available, but results
seem more modest. A recent Dutch study showed relevant
and sustained improvement in 15 out of 27 CLI patients.8
One uncontrolled Belgian study, in a similar population of
16 CLI patients with many cardiovascular risk factors,
suggested that in these patients results are modest and
restricted to the least affected patients.9 The estimated 50%
reduction in risk of major amputations is a conservative
estimate and takes into account that the effects in a West-
ern, older population with multiple risk factors may be less
than in the Asian population.
To allow for definite conclusions on the efficacy of cell
administration in CLI patients, group sequential interim
analysis will be performed. This statistical method allows
for a varying number of patients to be included in a trial,
depending on the difference in outcome between two
groups. On average, fewer patients are needed in a trial if
the expected difference in the primary outcome variable
appears to be real.10 Assuming that BM-MNC infusion will
reduce the risk of major amputation by 50%, it has been
estimated that with a two-sided alpha of 0.05 and a power
of 80%, approximately 110 to 160 patients need to be
enrolled in the JUVENAS Trial and followed for 6 months.
If important clinical differences between groups become
evident during an interim analysis, the trial will be stopped,
and patients will be offered the best treatment available. If
the observed benefit is ‘clearly’ larger, or if placebo treat-
ment appears to be better than BM-MNC infusion, early
termination of the trial may be recommended.
CURRENT STATUS
Recruitment of patients for the JUVENTAS Trial com-
menced in September 2006, and to date over 60 patients
have been included in the trial. After a start-up phase, the
speed of inclusion increased steadily, and recruitment of the
110th patient is currently expected by the end of 2011. If
inclusion is prolonged to 160 patients, inclusion is expectedto close by the end of 2012. Analysis and reporting is
expected to be completed a half year after inclusion has
ended. The trial has been submitted to the ClinicalTrials.gov
trial register under number NCT00371371.
DISCUSSION
Although progenitor cell-based therapy has emerged as
a promising new tool in the treatment of CLI, no definite
proof about its efficacy is yet available, since the clinical
studies thus far have been small and lacked double-blinded
controls. The JUVENTAS trial has been designed to inves-
tigate the effects of intra-arterial infusion of BM-MNC in
patients with CLI in a randomized, double-blind, placebo-
controlled manner, and to provide additional evidence for
efficacy and safety of cell-based therapeutic neovasculariza-
tion.
With regard to cell therapy, many questions are still
unanswered: for example, concerning the optimal cell pop-
ulation to be administered, the optimal route of adminis-
tration, the optimal dose, the need for multiple treatments,
and the impact of BM cell dysfunction.
Several uncontrolled studies, often in Asian popula-
tions, have showed that intramuscular (IM) administration
of BM-MNC is feasible and safe and has potential beneficial
clinical effects.4 Of the 10 studies (190 patients) inWestern
populations, five applied intra-arterial (IA) injection, either
alone11-13 or in combination with IM injections.8,14 Sev-
eral reasons for choosing IA administration over IM admin-
istration as the optimal delivery route can be identified: (a)
preclinical data suggest that IA injection leads to improved
survival of injected cells;4 (b) most CLI patients have
multi-level disease, including the femoropopliteal tract and
pedal arteries. These zones may be better reached by IA as
compared with IM calf injections;4 (c) extensive experience
exists and positive results have been reported on intra-
(coronary) artery administration of BM-MNC in patients
with myocardial ischemia (see meta analyses15,16); (d) in
preclinical studies similar results for intra-arterial versus
intramuscular injection on angiogenic activity were ob-
served.17
With regard to dosing, the JUVENTAS Trial chose to
administer progenitor cells obtained from 100 ml BM,
which can be aspirated under local anesthesia with a low risk
of adverse events (none thus far) in a repeated infusion
scheme. No criteria such as a minimal cell number, CD34
cell number, and/or percentage have been defined. This
strategy maximizes the amount of BM that is administered
to the patient. In other clinical trials thus far, varying doses
of injected MNC, with varying concentrations of CD34
cells have been used. In studies on BM-MNC administra-
tion in CLI patients, amounts of aspirated BM ranging
from 80 to 1000 ml have been reported, from which
varying amounts of MNC and different fractions of
CD34 cells retrieved.4 All of those studies have reported
beneficial effects on clinical outcome, and no consistent
evidence of a dose-response in humans has been reported.
In the JUVENTAS trial, all data on numbers of infused
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related to study outcome.
Studies in myocardial ischemia have shown that only a
limited number of cells are retained in the injured tissue. It
was assumed that repeated administration of cells would
lead to enhanced retainment of cells, and, therefore, a three
times intra-arterial infusion scheme was chosen. No previ-
ous studies have reported on BM-MNC dose escalations or
comparisons of different time points and frequencies of
injection. A recent small dose-escalating study was unable
to demonstrate differences between various dosages of
intramuscularly transplanted GCSF-mobilized CD34 cells,
but encouraged larger randomized controlled trials on this
topic.18
Several studies have demonstrated that circulating EPC
are reduced and dysfunctional in the presence of risk factors
for cardiovascular disease.19 Such functional impairment
has been shown to extend to BM-MNC. BM-MNC ob-
tained from patients with chronic ischemic heart disease has
profoundly reduced neovascularization capacity.20 In
PAOD, particularly in diabetes, reduced circulating EPC
numbers and function have been reported.21 One small
study showed lower circulating and BM EPC levels in
patients with limb ischemia compared with controls, with a
significant reduction in the mRNA expression level of EPC
markers in BM-MNC, suggesting lower angiogenic poten-
tial.22 It has been suggested that the more modest response
to BM-MNC therapy observed in Caucasian as compared
with Asian patients may be related to the higher prevalence
of cardiovascular risk factors and associated EPC dysfunction.8,9
A functional impairment of BM-MNC may limit the ther-
apeutic potential of autologous BM cell therapy. The
JUVENTAS Trial therefore includes a preclinical part that
focuses on the functional characterization of the BM-MNC
obtained from CLI patients. Functional characteristics of
the BM-MNC will be related to clinical outcome. Such a
translational approach may lead to the identification of
predictive assays or markers for therapeutic efficacy andmay
eventually yield strategies to improve therapeutic efficacy.
CONCLUSIONS AND IMPLICATION
The JUVENTAS Trial will be the largest randomized,
double-blind, placebo-controlled clinical trial yet con-
ducted to evaluate the clinical effects of intra-arterial infu-
sion of BM-MNC in patients with CLI. The results from
this trial will further strengthen the evidence on the efficacy
of cell-based therapy for CLI. If repeated intra-arterial
infusion of autologous BM-MNC is beneficial, it could
become a novel treatment to prevent amputation in pa-
tients with CLI.
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F.L. Moll, MD, PhD; R.E.G. Schutgens, MD, PhD;
I.C.M. Slaper-Cortenbach, PhD; Y. van der Graaf, MD,
PhD; P.A. Doevendans, MD, PhD; and W.P.Th.M. Mali,
MD, PhD.COMMENTARYThomas L. Forbes, MD, London, Ontario, Canada
Over the last while, several investigators have explored the role of
bone marrow-derived mononuclear cells in promoting angiogenesis
or neovascularization in patients with critical limb ischemia (CLI)
who have no other treatment option. The JUVENTAS (reJUVenat-
ing ENdothelial progenitor cells via Transcutaneous intra-Arterial
Supplementation) trialists describe the background and rationale of
this randomized study. There are a number of questions that perme-
ate this and other similar studies.
Study subjects include patients with critical limb ischemia and
severe claudication who are not candidates for revascularization as
determined by a team of radiologists and surgeons. This is consis-
tent with other studies, but what does it mean? Revascularization
suitability is a criterion that is open to disagreement and variability.
It certainly adds a subjective component to patient selection and
can make it difficult to compare the results of different studies.
The study investigators’ decision to include severe claudicants
raises some issues. First of all, some would argue that claudicants
are more likely to be suitable for intervention and are less likely to
have no revascularization options than those with CLI. Secondly,
claudicants are less likely to undergo major amputation and, as thissize calculation, the more claudicants included, the higher the
chance of an underpowered study. According to the investigators,
only three claudicants have been included in the over 60 subjects
recruited to date, so this may not be a major issue.
Several practical questions remain as well, including mode of
delivery. Is the best method of delivery intra arterial, as in JUVEN-
TAS, or intramuscular, or a combination as used by other investi-
gators?1 Additionally, what is the best method of determining
neovascularization? Is it magnetic resonance angiography, as in
this study, or angiography, duplex ultrasound, and/or ankle bra-
chial indices, as used by others?
This is an important and exciting area of investigation involv-
ing patients who often have no alternative but major amputation.
Hopefully, this randomized trial will clarify some of the issues
regarding this form of therapy.
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